Faron Pharmaceuticals Sees Increased Share Liquidity Following A&B Divestment

An update from Faron Pharmaceuticals Oy ( (GB:FARN) ) is now available.

Faron Pharmaceuticals Ltd announced that A&B (HK) Company Ltd has divested its entire shareholding of 3,559,893 ordinary shares, which represented approximately 3.40% of Faron’s issued share capital. This divestment, initially part of a strategic agreement involving Faron’s drug candidate Traumakine®, was made as Faron shifts its focus to its lead asset, bexmarilimab. The sale by A&B has increased the liquidity of Faron’s shares in the market, potentially impacting the company’s market dynamics and stakeholder interests.

More about Faron Pharmaceuticals Oy

Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. The company’s lead asset, bexmarilimab, is an investigational immunotherapy designed to overcome resistance to existing treatments by targeting myeloid cell function and igniting the immune system. Bexmarilimab is currently being investigated in Phase I/II clinical trials for patients with hematological cancers.

YTD Price Performance: -4.39%

Average Trading Volume: 62,007

Technical Sentiment Signal: Sell

Current Market Cap: £259.2M

See more data about FARN stock on TipRanks’ Stock Analysis page.